Literature DB >> 9067953

Cyclosporine in the therapy of steroid-resistant idiopathic nephrotic syndrome.

P Niaudet1, A Fuchshuber, M F Gagnadoux, R Habib, M Broyer.   

Abstract

Steroid-resistant nephrotic syndrome with either minimal changes or focal and segmental glomerular sclerosis on initial biopsy is a severe condition as more than 50% of patients with the disease progress to end-stage renal failure within 10 years. We recently identified a distinct form of idiopathic nephrotic syndrome with an autosomal recessive mode of inheritance and were able to map the gene on the long arm of chromosome 1. The absence of recurrence of the disease after renal transplantation suggest a primary defect in a glomerular basement membrane protein. Several reports suggest that cyclosporine is effective in a proportion of patients with steroid-resistant idiopathic nephrotic syndrome, particularly when used in combination with corticosteroids. There are also data suggesting that high doses of cyclosporine may be necessary in patients with severe hypercholesterolemia. However, cyclosporine treatment should be carefully monitored in view of the high risk of nephrotoxicity, as shown by the results of repeat renal biopsies. The beneficial role of cyclosporine in recurrent steroid-resistant nephrotic syndrome is still debated. Preliminary observations suggest that the early use of intravenous cyclosporine may be effective in these patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9067953

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  8 in total

1.  Decreased cyclosporine exposure during the remission of nephrotic syndrome.

Authors:  Mara Medeiros; José Pérez-Urizar; Natalia Mejía-Gaviria; Eduardo Ramírez-López; Gilberto Castañeda-Hernández; Ricardo Muñoz
Journal:  Pediatr Nephrol       Date:  2006-10-20       Impact factor: 3.714

2.  Intravenous cyclophosphamide in steroid-resistant nephrotic syndrome.

Authors:  Anurag Bajpai; Arvind Bagga; Pankaj Hari; Amit Dinda; Rajendra N Srivastava
Journal:  Pediatr Nephrol       Date:  2003-03-21       Impact factor: 3.714

3.  Efficacy of intravenous pulse cyclophosphamide treatment versus combination of intravenous dexamethasone and oral cyclophosphamide treatment in steroid-resistant nephrotic syndrome.

Authors:  Mukta Mantan; Chenni S Sriram; Pankaj Hari; Amit Dinda; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2008-06-20       Impact factor: 3.714

Review 4.  Corticosteroid-resistant nephrotic syndrome with focal and segmental glomerulosclerosis : an update of treatment options for children.

Authors:  Jochen H H Ehrich; Lars Pape; Mario Schiffer
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

5.  Cyclosporine and steroid therapy in children with steroid-resistant nephrotic syndrome.

Authors:  Yuko Hamasaki; Norishige Yoshikawa; Shinzaburo Hattori; Satoshi Sasaki; Kazumoto Iijima; Koichi Nakanishi; Takeshi Matsuyama; Kenji Ishikura; Nahoko Yata; Tetsuji Kaneko; Masataka Honda
Journal:  Pediatr Nephrol       Date:  2009-11       Impact factor: 3.714

6.  Long-term outcome of idiopathic steroid-resistant nephrotic syndrome in children.

Authors:  Aya Inaba; Yuko Hamasaki; Kenji Ishikura; Riku Hamada; Tomoyuki Sakai; Hiroshi Hataya; Fumiyo Komaki; Tetsuji Kaneko; Masaaki Mori; Masataka Honda
Journal:  Pediatr Nephrol       Date:  2015-09-03       Impact factor: 3.714

7.  Prediction of high-degree steroid dependency in pediatric idiopathic nephrotic syndrome.

Authors:  Béatrice Letavernier; Emmanuel Letavernier; Sandrine Leroy; Valérie Baudet-Bonneville; Albert Bensman; Tim Ulinski
Journal:  Pediatr Nephrol       Date:  2008-07-11       Impact factor: 3.714

8.  Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome-a randomized controlled multicentre trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie.

Authors:  Christian Plank; Veronica Kalb; Bernward Hinkes; Friedhelm Hildebrandt; Olaf Gefeller; Wolfgang Rascher
Journal:  Pediatr Nephrol       Date:  2008-05-15       Impact factor: 3.714

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.